Before joining NicOx in April 2007, Mr. Sharma led the Strategic Marketing and Business Analysis function at Biovail Pharmaceutical Inc. in the U.S., where he was responsible for new product commercialization and strategic life cycle management across five therapeutic areas, with a special focus on the Ultram® ER franchise for the treatment of chronic pain in adults and the Wellbutrin® XL franchise for the treatment of depression.

Previously, he worked at Sanofi-Aventis and its predecessor companies in a variety of positions with increasing responsibility, culminating in his nomination as Director, New Products Commercialization; Metabolism & Cardiovascular; Global Marketing. He has played a significant role in the successful launch, commercialization or life cycle management of numerous products in the US, Canada and globally, such as Actonel® for the treatment of osteoporosis and Cardizem®, Lovenox® and Altace® for treating cardiovascular diseases.

Mr. Sharma obtained his MBA in 1997 from the Richard Ivey School of Business at the University of Ontario in Canada and was designated as an Ivey Scholar for Scholastic Excellence.